INTI (INTI) Stock Analysis
Verdict: AVOID
Severe cash burn with under 9 months of runway and negative equity creates extreme dilution risk despite clinical pipeline potential.
Investment score: 13/100
The AI model evaluates INTI as an AVOID due to zero revenue, an ongoing cash burn rate of $3.23M per year against $2.38M in cash (~8.8 months runway), negative equity of -$1.29M, and acute dilution risk.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| CNSY | -0.00 | 2.52 | 3.33 | -0.52 | — | -6.21 |
| BIVI | -0.56 | 1.32 | 0.00 | -0.22 | — | 0.00 |
| PASG | -0.42 | 3.46 | 0.00 | 0.27 | — | 0.00 |
| MBRX | -0.04 | 0.37 | 0.00 | 0.10 | — | 0.00 |
| SYBX | -21.60 | 1.20 | 0.00 | -0.10 | — | 0.00 |